Affinity Wealth Management LLC Boosts Stock Holdings in Eli Lilly and Company $LLY

Affinity Wealth Management LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 13,029 shares of the company’s stock after acquiring an additional 206 shares during the quarter. Eli Lilly and Company accounts for approximately 1.6% of Affinity Wealth Management LLC’s portfolio, making the stock its 18th largest holding. Affinity Wealth Management LLC’s holdings in Eli Lilly and Company were worth $10,157,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of LLY. Brighton Jones LLC boosted its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after acquiring an additional 40 shares during the last quarter. BridgePort Financial Solutions LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $180,000. Alpha Wealth Funds LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth $477,000. Finally, Lighthouse Financial LLC purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth about $3,351,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Trading Down 0.6%

Shares of LLY opened at $742.51 on Thursday. The business’s 50-day moving average price is $736.05 and its 200-day moving average price is $768.68. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.30. The stock has a market cap of $702.75 billion, a PE ratio of 48.53, a P/E/G ratio of 1.04 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion for the quarter, compared to analysts’ expectations of $14.40 billion. During the same period in the prior year, the business posted $3.92 earnings per share. The company’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the topic of a number of research analyst reports. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Cantor Fitzgerald cut their price target on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating on the stock in a report on Wednesday, August 13th. Leerink Partnrs downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 7th. Morgan Stanley reissued an “overweight” rating and issued a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Finally, HSBC upgraded Eli Lilly and Company from a “reduce” rating to a “hold” rating and boosted their price objective for the company from $675.00 to $700.00 in a research note on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $939.61.

Insider Buying and Selling

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was bought at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares of the company’s stock, valued at $47,903,686.74. The trade was a 2.14% increase in their position. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last 90 days. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.